These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23046206)

  • 41. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Page CP; Matera MG
    Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
    Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease.
    Avdeev SN; Trushenko NV
    Ter Arkh; 2019 Mar; 91(3):76-85. PubMed ID: 31094464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
    Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
    BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.
    D'Urzo A; Singh D; Garcia Gil E
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):13. PubMed ID: 28235977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of aclidinium on determinants of COPD severity: symptoms and quality of life.
    Contoli M; Solidoro P; Di Marco F; Scichilone N; Corsico A; Braido F; Santus P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3043-3050. PubMed ID: 27980401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
    Jansat JM; Lamarca R; Garcia Gil E; Ferrer P
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):460-8. PubMed ID: 19640353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
    Beeh KM; Watz H; Puente-Maestu L; de Teresa L; Jarreta D; Caracta C; Garcia Gil E; Magnussen H
    BMC Pulm Med; 2014 Dec; 14():209. PubMed ID: 25539654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
    Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study.
    Kamei T; Nakamura H; Nanki N; Minakata Y; Matsunaga K; Mori Y;
    BMJ Open; 2019 Jul; 9(7):e024114. PubMed ID: 31350236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Joos GF
    Drugs Today (Barc); 2012 Dec; 48(12):757-63. PubMed ID: 23243632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
    Zou Y; Xiao J; Yang DH; Li J; Chen Q
    COPD; 2016 Aug; 13(4):499-508. PubMed ID: 26846588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Matera MG
    Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update on the efficacy and safety of aclidinium bromide in patients with COPD.
    Alagha K; Bourdin A; Tummino C; Chanez P
    Ther Adv Respir Dis; 2011 Feb; 5(1):19-28. PubMed ID: 20884687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
    Blasi F; Canonica GW; Miravitlles M
    Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
    ZuWallack AR; ZuWallack RL
    Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.